Gyre Therapeutics (GYRE)
NASDAQ:GYRE
Top Page
Gyre Therapeutics
(NASDAQ:GYRE)
Select Model
Select Model
Rating:56Neutral
Price Target:
$7.00
▲(2.79% Upside)
Action:ReiteratedDate:03/23/26
The score is primarily supported by improving profitability and a low-leverage balance sheet, plus positive regulatory/M&A milestones. It is held back by weak and volatile cash generation, bearish technicals (below major moving averages with negative MACD), and a very high P/E valuation.
Positive Factors
Improved Profitability
Sustained return to positive net income and exceptionally high gross margins signal that core products are profitable and scalable. Over the next 2–6 months this improves internal funding capacity for R&D and commercialization, reduces refinancing pressure, and supports durable operating leverage if revenue growth continues.
Negative Factors
Weak Cash Generation
Persistent negative free cash flow and weak operating cash conversion mean reported profits are not translating into durable liquidity. This structural cash shortfall raises reliance on equity financing or asset sales, increases dilution risk, and constrains steady funding for commercialization, making execution of long-term plans more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Profitability
Sustained return to positive net income and exceptionally high gross margins signal that core products are profitable and scalable. Over the next 2–6 months this improves internal funding capacity for R&D and commercialization, reduces refinancing pressure, and supports durable operating leverage if revenue growth continues.
Read all positive factors
Gyre Therapeutics (GYRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$647.42M
Dividend YieldN/A
Average Volume (3M)102.52K
Price to Earnings (P/E)125.5
Beta (1Y)1.83
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees579
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding91,314,010
10 Day Avg. Volume112,833
30 Day Avg. Volume102,519
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)5.95
Price to Sales (P/S)5.41
P/FCF Ratio-3.50K
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue5.36
Enterprise Value/Gross Profit5.62
Enterprise Value/Ebitda42.48
Forecast
1Y Price Target
$19.00Price Target Upside179.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$148.00M
Gyre Therapeutics Business Overview & Revenue Model
Company Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug appro...
How the Company Makes Money
null...
Gyre Therapeutics Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
83
Very Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 116.59M | 105.76M | 113.45M | 102.29M | 7.34M |
| Gross Profit | 111.17M | 101.87M | 108.81M | 97.50M | -332.00K |
| EBITDA | 14.01M | 17.82M | 20.33M | 10.33M | -87.64M |
| Net Income | 5.03M | 12.09M | -92.93M | 2.30M | -87.93M |
Balance Sheet | |||||
| Total Assets | 166.13M | 125.41M | 116.54M | 84.75M | 55.66M |
| Cash, Cash Equivalents and Short-Term Investments | 52.42M | 26.67M | 33.51M | 25.18M | 46.85M |
| Total Debt | 939.00K | 1.60M | 409.00K | 613.00K | 2.38M |
| Total Liabilities | 23.85M | 27.00M | 102.59M | 12.54M | 14.57M |
| Stockholders Equity | 106.03M | 63.32M | -15.83M | 42.52M | 41.09M |
Cash Flow | |||||
| Free Cash Flow | -180.00K | -6.77M | 17.31M | 5.68M | -84.59M |
| Operating Cash Flow | 1.01M | -3.64M | 25.89M | 10.68M | -83.75M |
| Investing Cash Flow | -474.00K | -19.88M | -19.76M | -13.81M | 48.19M |
| Financing Cash Flow | 24.38M | 2.10M | 2.50M | 0.00 | 49.55M |
Gyre Therapeutics Technical Analysis
Negative
6.81
Price Trends
7.74
Negative
7.69
Negative
7.67
Negative
Market Momentum
-0.21
Negative
44.58
Neutral
57.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Negative. The current price of 6.81 is below the 20-day moving average (MA) of 7.19, below the 50-day MA of 7.74, and below the 200-day MA of 7.67, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 44.58 is Neutral, neither overbought nor oversold. The STOCH value of 57.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GYRE.
Gyre Therapeutics Risk Analysis
Gyre Therapeutics disclosed 97 risk factors in its most recent earnings report. Gyre Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gyre Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.08B | -39.12 | -20.02% | ― | ― | 12.45% | |
61 Neutral | $2.21B | ― | -23.43% | ― | 31.11% | -46.75% | |
56 Neutral | $647.42M | 125.48 | 5.46% | ― | ― | ― | |
55 Neutral | $2.00B | -13.06 | -34.75% | ― | ― | -17.01% | |
54 Neutral | $987.06M | -37.98 | -444.41% | ― | ― | -13.14% | |
54 Neutral | $1.50B | -13.24 | -28.72% | ― | ― | -44.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GYRE
Gyre Therapeutics
7.09
-0.20
-2.74%
KALV
KalVista Pharmaceuticals
19.27
8.73
82.83%
TERN
Terns Pharmaceuticals
52.66
50.52
2360.75%
DAWN
Day One Biopharmaceuticals
21.44
14.68
217.16%
TYRA
Tyra Bioscience
37.13
29.58
391.79%
MBX
MBX Biosciences, Inc.
31.66
25.39
404.94%
Gyre Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Gyre Therapeutics Files NDA in China for F351
Positive
Mar 23, 2026
On March 22, 2026, Gyre Pharmaceuticals submitted a New Drug Application to China’s Center for Drug Evaluation for F351 (Hydronidone), its lead therapy for chronic hepatitis B-induced liver fibrosis. The filing marked a key regulatory milest...
Business Operations and StrategyFinancial Disclosures
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs
Positive
Mar 12, 2026
At a March 10, 2026 investor conference, Gyre Therapeutics outlined expectations that its Hydronidone (F351) liver fibrosis program could generate approximately $400 million to $600 million in revenue within five years, while its ETUARY lung fibro...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger
Positive
Mar 2, 2026
On March 2, 2026, Gyre Therapeutics agreed to acquire privately held Cullgen Inc. in an all-stock deal valuing Cullgen at roughly $300 million, with Cullgen to become a wholly owned subsidiary and the merger structured as a tax-free reorganization...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Gyre Therapeutics Advances Hydronidone Toward China Approval
Positive
Jan 5, 2026
On January 5, 2026, Gyre Therapeutics announced that its majority-owned Chinese subsidiary, Gyre Pharmaceuticals, had completed a Pre-New Drug Application communication meeting with China’s Center for Drug Evaluation, which agreed that exist...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.